Janssen Announces US FDA Approval of INVEGA HAFYERA™ (6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia - PRNewswire

Submitted by Anonymous (not verified) on Wed, 09/01/2021 - 12:00

Janssen Announces US FDA Approval of INVEGA HAFYERA™ (6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia PRNewswire

Log in to post comments